---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-24-000008"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:31:51.549950+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma closes $5M secured convertible note with Daewoong; 15.79% interest

## Summary
- Issued $5M senior secured convertible note to Daewoong Pharmaceutical as initial closing of $15M subscription agreement.
- Note accrues interest at 15.79% per annum, matures March 24, 2027.
- Automatically converts at 1.3x principal into shares if AEON raises ≥$30M equity financing at ≥$1.00/share.
- Optional conversion at Daewoong's election upon positive Phase 3 ABP-450 data or change of control.
- Proceeds to fund late-stage clinical development of ABP-450 for migraine and for working capital.

## SEC filing metadata
- accession: 0001837607-24-000008
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000008/0001837607-24-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000008/aeon-20240324x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-24-000008
- JSON: https://secwatch.observer/filing/0001837607-24-000008.json
- Plain text: https://secwatch.observer/filing/0001837607-24-000008.txt

## Key facts
- Debt Financings
  AEON Biopharma, Inc. incurred convertible notes of $5,000,000 with Daewoong Pharmaceutical Co., LTD. at 15.79% maturing March 24, 2027.
  - Instrument: convertible notes
  - Principal: $5,000,000
  - Counterparty: Daewoong Pharmaceutical Co., LTD.
  - Rate: 15.79%
  - Maturity: March 24, 2027
  - Event: incurrence
  source text: on March 24, 2024, AEON issued and sold to Daewoong one senior secured convertible note (the “Convertible Note”) in the principal amount of $5,000,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000008/0001837607-24-000008-index.htm
- Material Agreements
  AEON Biopharma, Inc. entered into Subscription Agreement with Daewoong Pharmaceutical Co., LTD. valued at up to $15.0 million (effective 2024-03-19).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: Daewoong Pharmaceutical Co., LTD.
  - Value: up to $15.0 million
  - Effective: 2024-03-19
  source text: on March 19, 2024, AEON Biopharma, Inc. (“AEON” or the “Company”) and AEON Biopharma Sub, Inc., a subsidiary of the Company (“AEON Sub”), entered into a subscription agreement (the “Subscription Agreement”) with Daewoong Pharmaceutical Co., LTD. (“Daewoong”) relating to the sale and issuance by the Company of senior secured convertible notes in the principal amount of up to $15.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000008/0001837607-24-000008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.